Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma

Ranjith Babu
D Cory Adamson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA

Abstract: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and is universally fatal. Despite surgical resection, radiotherapy, and systemic chemotherapy, the median overall survival is less than 15 months. As current therapies are not tumor-specific, treatment commonly results in toxicity. The epidermal growth factor receptor variant III (EGFRvIII) is a naturally occurring mutant of EGFR and is expressed on approximately 20% to 30% of GBMs. As it is not expressed on normal cells, it is an ideal therapeutic target. Rindopepimut is a peptide vaccine which elicits EGFRvIII-specific humoral and cellular immune responses. Phase I and II clinical trials have demonstrated significantly higher progression-free and overall survival times in vaccinated patients with EGFRvIII-expressing GBM tumors. Side effects are minimal and mainly consist of hypersensitivity reactions. Due to the efficacy and safety of rindopepimut, it is a promising therapy for patients with GBM. Currently, rindopepimut is undergoing clinical testing in an international Phase III trial for newly diagnosed GBM and a Phase II trial for relapsed GBM.

Keywords: CDX-110, EGFRvIII, glioblastoma, immunotherapy, PEPvIII

Core evidence clinical impact summary for rindopepimut for EGFRvIII-positive glioblastoma

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Evidence</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease-oriented evidence</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Induction of cellular and humoral immune responses</td>
<td>Preclinical, phase I (VICTORI: N = 12) and phase II (ACTIVATE: N = 18; ACT II: N = 22; ACT III: N = 65) studies demonstrating the induction of EGFRvIII-specific cellular and humoral immune responses</td>
<td>Vaccination results in specific antitumoral activity towards EGFRvIII-expressing cells with no cross-reactivity with normal cells</td>
</tr>
<tr>
<td><strong>Patient-oriented evidence</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progression-free survival (PFS)</td>
<td>Multicenter phase II clinical trials demonstrating significantly higher PFS compared to historic controls and previous phase III clinical trials when added to the current standard of care</td>
<td>Significantly improves patient quality of life and overall survival</td>
</tr>
</tbody>
</table>

(Continued)
Introduction

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. These tumors are classified by the World Health Organization (WHO) as grade IV gliomas and are highly aggressive, with recurrence occurring in all cases. Despite surgical resection, radiotherapy, and systemic chemotherapy, the median overall survival (OS) is less than 15 months. Additionally, patients with recurrent tumors have an even worse prognosis. While current therapies are able to increase OS and progression-free survival (PFS), these therapies damage normal tissue and typically fail. As a result, there is a need for more specific and effective therapies which are able to selectively target tumor cells without damaging normal brain cells.

Immunotherapy has become an attractive therapeutic modality. The identification of tumor-associated antigens has allowed for the manipulation of the immune system to eliminate neoplastic cells without affecting normal parenchyma. Currently, a variety of immunotherapies have been approved for the treatment of various cancers, with many in advanced clinical trials. These treatments are composed of cellular and recombinant components that utilize innate and adaptive immune responses. Immunotherapies consist of immune-modulating and tumor-specific antibodies, adoptive cell transfer, and cancer vaccines.

While tumor-specific monoclonal antibodies such as rituximab and trastuzumab are the highest grossing cancer therapies, there is increasing interest in the use of vaccines to activate the immune system against tumor antigens. One such target in GBM is the mutated epidermal growth factor receptor variant III (EGFRvIII), which is a tumor-specific epitope expressed on approximately 20%–30% of GBMs, 78% of breast carcinomas, 73% of ovarian carcinomas, 42% of head and neck squamous cell carcinomas, and 39% of non-small-cell lung cancers. EGFRvIII expression typically occurs in the presence of wild-type EGFR overexpression, occurring in 58% to 65% of such cases. As wild-type EGFR overexpression most frequently occurs in primary (de novo) GBM and rarely in secondary GBM (those that progress from low-grade tumors), EGFRvIII expression is most common in primary tumors. Also some studies have demonstrated a male predominance for EGFRvIII expression in GBM.

While EGFRvIII expression typically occurs in the presence of wild-type EGFR overexpression, occurring in 58% to 65% of such cases. As wild-type EGFR overexpression most frequently occurs in primary (de novo) GBM and rarely in secondary GBM (those that progress from low-grade tumors), EGFRvIII expression is most common in primary tumors. Also some studies have demonstrated a male predominance for EGFRvIII expression in GBM.

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Evidence</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall survival</td>
<td>Multicenter phase II clinical trials demonstrating significantly higher overall survival compared to historic controls and previous phase III clinical trials when added to the current standard of care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACTIVATE (26.0 vs 15.0 months (matched cohort))</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACT II (23.6 vs 15.0 months (historical cohort))</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACT III (24.6 vs 15.0 months (historical cohort))</td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td>Phase I (VICTORI: N = 12) and II (ACTIVATE: N = 18; ACT II: N = 22; ACT III: N = 65) studies demonstrating minimal adverse effects which mainly consisted of reactions that were not more severe than grade II toxicity</td>
<td></td>
</tr>
<tr>
<td>Economic evidence</td>
<td>Unknown as rindopepimut has not yet received marketing authorization</td>
<td></td>
</tr>
</tbody>
</table>
ligand-independent mutant enhances tumorigenicity, tumor cell migration, and resistance to chemoradiotherapy.22–27

As it is not expressed on normal cells, EGFRvIII is an effective target for immunotherapies.10,14 One such therapy is rindopepimut (PEPvIII-KLH; CDX-110; Celldex Therapeutics, Phillipsburg, NJ), an EGFRvIII-specific, 14-mer peptide which when coupled with keyhole limpet hemocyanin (KLH) elicits humoral and cellular immune responses.28,29 Currently, rindopepimut is undergoing clinical testing in a Phase III trial for newly diagnosed GBM (NCT01480479), a Phase II trial with granulocyte-macrophage colony-stimulating factor (GM-CSF) for relapsed GBM (NCT01498328), and a Phase I trial for use in children with diffuse intrinsic pontine gliomas (NCT01058850). This review summarizes the current evidence for the use of rindopepimut in GBM.

### Barriers to immunotherapy for brain tumors

For immunotherapies to initiate immune responses, CD4+ (helper) and CD8+ (cytotoxic) T cells must be activated by the recognition of antigens on the class I or II major histocompatibility complexes (MHCs) found on antigen-presenting cells (APCs).30 However, full activation only occurs following a co-stimulatory signal between T cells and APCs. The absence of this signal, which is necessary for T cell proliferation and differentiation, results in anergy or cell death.

Several challenges are present for the use of immunotherapy for intracerebral tumors. Firstly, the brain is considered to be immunologically isolated compared to other organs. This was suggested by studies showing that intracranially implanted tissue grafts in animals did not result in rejection.31 This is thought to be due to the absence of lymphatic architecture, the presence of the blood–brain barrier (BBB), and paucity of APCs within the brain.32,33 However, more recent studies have shown that the brain is not as isolated as previously thought. While there are no draining lymph nodes in the brain, antigens within the central nervous system (CNS) can drain in the cerebrospinal fluid (CSF) through Virchow–Robin spaces to cervical and nasal lymph nodes.34–36 Also though the BBB was thought to limit leukocyte movement into the CNS, numerous studies have demonstrated lymphocyte BBB penetration.37–39

Activated T cells highly express molecules such as leukocyte-function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-4) which allow for their migration across the BBB.40–42 The production of inflammatory mediators by the peripheral immune system can also increase the permeability of the BBB, allowing for activated macrophages and dendritic cells (DCs) to enter the CNS. Other mechanisms of leukocyte entry into the CNS include transmigration via transient pore-like structures within the endothelial cells of the BBB, and extravasation across the fenestrated endothelium of the choroid plexuses.43–46 Additionally, BBB composition has been shown to vary between different brain regions, resulting in various degrees of cellular immune surveillance.47 Finally, while there is not an abundance of APCs within the CNS, macrophages, DCs, and microglia can act as effective APCs to stimulate T-cell responses.48–50 As studies have demonstrated
microglial density to differ by up to one order of magnitude in various brain regions, response to immunotherapies may also be location-dependent.\(^{51}\)

In addition to the barriers posed by the normal brain, GBM cells elicit responses that often make development of treatments challenging (Figure 2). Patients with GBM have been shown to have systemic immune deficits, with lymphopenia of natural killer (NK) and CD4+ T cells, and dysregulation of cytokine profiles.\(^{52-56}\) Additionally, leukocyte impairments have been reported including decreased T- and B-cell proliferation, antigen presentation, cytokine and antibody production, and NK cell cytotoxicity. These effects are thought to be partly due to the secretion of molecules such as transforming growth factor-\(\beta\) (TGF-\(\beta\)), interleukin-10 (IL-10), prostaglandin E\(_2\) (PGE\(_2\)), and gangliosides.\(^{57}\) Additionally, GBM cells express a multitude of immunosuppressive molecules, preventing the anti-tumor activity of leukocytes. The expression of the co-stimulatory inhibitory molecule B7-H1 on GBM-associated cancer-initiating cells triggers T cell apoptosis.\(^{58,59}\) HLA-G, a nonclassical MHC class I molecule, is also expressed on GBM cells and can prevent the efficient priming of cytotoxic T cells, inhibit allograft responses, and increase resistance to alloreactive lysis.\(^{60}\) Similarly, the expression of CD70 on GBM cells results in T- and B-cell apoptosis via the interaction with CD27.\(^{51}\) Another contributor to immunosuppression in patients with GBM is the increased levels of CD4+/CD25+ T\(_{reg}\) despite systemic lymphopenia.\(^{62}\) These cells are attracted to the tumor environment in high-grade astrocytic tumors due to the secretion of CCL2, and result in the inhibition of T cell cytokine secretion and proliferation.\(^{63-65}\) As a multitude of mechanisms contribute to immunosuppression in patients with GBM, a multimodal approach is necessary to reduce the immunosuppressive effects of the tumor microenvironment, and enhance the ability to mount an effective immune response within the CNS.

**EGFRvIII as an immunotherapeutic target**

EGFR is a transmembrane glycoprotein which contains an extracellular ligand-binding domain and a cytoplasmic domain containing a tyrosine kinase.\(^{66}\) It is activated upon binding of its ligands including the epidermal growth factor (EGF) or TGF\(\alpha\), resulting in receptor dimerization and activation of the tyrosine kinase domain. This turns on oncogenic pathways which may account for the poorer survival seen in GBM patients with EGFR amplification.\(^{67}\) This amplification and resulting overexpression of the EGFR protein is the most common genetic alteration in GBM, occurring in approximately 40% of

![Figure 2](https://www.dovepress.com/submit-your-manuscript) Various immunosuppressive factors expressed and secreted by glioblastoma cells.
newly diagnosed cases.67,68 In tumors that overexpress EGFR, up to 75% of cases have rearrangements of the EGFR gene that lead to the expression of mutant forms.15,69–72 The most common EGFR mutation is EGFRvIII which results from an in-frame deletion of 267 amino acids in the extracellular domain (Figure 1).73 This receptor has constitutive tyrosine kinase activity and has important pro-oncogenic effects including enhancing proliferation, radio- and chemotherapeutic resistance, and migration, while inhibiting apoptosis.22–27,74,75 While 37%–86% of cells within EGFRvIII-expressing tumors express this receptor, EGFRvIII positive cells are able to secrete membrane-derived microvesicles with EGFRvIII which then merge with the plasma membranes of negative cells, conferring the same oncogenic advantages.76,77 As EGFRvIII contains an antigenic junction with a novel glycine residue and is not expressed on normal tissues, it is an effective target for immunotherapy.12

A variety of immunotherapies targeting EGFRvIII are currently under investigation including monoclonal antibodies, dendritic cell vaccination therapy, genetically modified T cells, and peptide vaccines. Various naked monoclonal antibodies have been shown to be specific for EGFRvIII and are able to elicit antitumor activity via Fc- and Fab-mediated activity.78–82 Monoclonal antibodies conjugated to toxins have also demonstrated significant cytotoxic activity against EGFRvIII-expressing tumors.83,84 Dendritic cell vaccination utilizes the antigen-presenting properties of dendritic cells to initiate antitumor responses. In vivo and human studies have demonstrated peptide-pulsed dendritic cells to induce EGFRvIII-specific cell-mediated immunity.85 More recently, genetically engineered T cells which express chimeric immune receptors have been shown to specifically lyse EGFRvIII-expressing gliomas cells in vitro and in vivo studies.86 While these therapies are all attractive therapeutic modalities, peptide vaccines are one of the most studied and well understood immunotherapies. The most promising peptide vaccine utilizes a peptide derived from the novel fusion junction amino acid sequence of EGFRvIII. This vaccine consists of PepvII (H-Leu-Glu-Glu-Lys-Lys-Gln-Asn-Tyr-Val-Val-Thr-Asp-His-Cys-OH), an EGFRvIII-specific 14-mer peptide, and KLH.28 As it is able to activate humoral and cellular immunoreactivity, and has been shown to induce EGFRvIII-specific immune responses in preclinical and clinical studies,29,87–89

**Detection of EGFRvIII mutations**

Due to the potential prognostic and therapeutic importance of EGFRvIII, its efficient detection is necessary for both laboratory and clinical evaluation. As one of the most common methods of tissue preservation is formalin fixation plus paraffin embedding (FFPE), immunohistochemistry (IHC) is widely used as an accurate and reliable method for detecting EGFRvIII expression in stored samples.8,10,19,90,91 A variety of monoclonal and polyclonal antibodies have been developed which specifically recognize EGFRvIII and are commonly used for evaluating its expression in clinical studies. EGFRvIII can also be detected in fresh frozen and FFPE tissue using real-time reverse transcription-polymerase chain reaction (RT-PCR) and Southern blot assays.90,91

**Preclinical studies**

Monoclonal antibodies targeted to EGFRvIII have shown to exhibit effective antitumor activity in in vitro and in vivo models. Treatment with unarmored murine IgG2a (Y10) and IgG1 (L8A4) monoclonal antibodies targeting EGFRvIII significantly inhibited tumor growth, though only treatment with IgG2a resulted in tumor-free survival after treatment was discontinued.82 Though intraperitoneal therapy did not increase the median survival of mice with intracranial EGFRvIII B16 melanomas, single intratumoral injections of Y10 increased survival by 286%, with 26% of mice becoming long-term survivors (P < 0.001). The in vivo mechanism of action of Y10 was seen to be Fc receptor-dependent while being independent of T cells, NK cells, granulocytes, and complement.

Immunotherapy using PEPvIII-KLH has also been effective against intracranial EGFRvIII-expressing tumors. Immunization of mice with DCs mixed with PEPvIII-KLH resulted in an approximately 600% increase in median survival, with 63% becoming long-term survivors.92 Also treatment with this mixture resulted in long-lasting protection as all rechallenged mice survived. Immunization with DCs mixed with PEPvIII-KLH produced EGFRvIII-specific IgG2a antibodies, correlating with antitumor activity. Another study demonstrated that a single dose of PEPvIII-KLH in Freund’s complete adjuvant increased median survival by 26% in mice with EGFRvIII-expressing intracerebral tumors (P = 0.0076).89 It was also seen that EGFRvIII expression was lost in 80% of relapsing tumors after vaccination, suggesting that EGFRvIII-negative escape is a potential mechanism of treatment failure (wild-type EGFR status was unknown in this study). Vaccination with PEPvIII-KLH resulted in humoral responses that could mediate antibody-dependent cellular cytotoxicity (ADCC), with the transfer of serum from vaccinated mice inducing antitumoral activity. The efficacy of PEPvIII-KLH was also seen to be dependent on CD8+ T and NK cells.
Clinical studies

Due to the success of PEPvIII-KLH in in vivo studies, several clinical trials were designed. The first clinical trial (Phase I; VICTORI) was conducted at the Duke University Medical Center and enrolled 15 adults with newly diagnosed GBM. However, as three patients had tumor progression during external beam radiotherapy and were not vaccinated, the data of 12 patients were analyzed. The median age was 42 years, with the majority of patients (58.3%) having a KPS of 100 (mean: 95.8). Patients underwent leukapheresis to obtain peripheral blood mononuclear cells (PBMC) for the generation of DCs and immunologic monitoring. DCs were then pulsed with PEPvIII-KLH and administered intradermally every 2 weeks at doses up to 1.1 X 10⁹ DCs in three equal doses. Patients were monitored for tumor progression and toxicity. There were no cases with serious adverse effects beyond grade II toxicity. While patients had increased erythrocyte sedimentation rate and rheumatoid factor levels, these increases were minimal and did not result in clinical symptoms. Immunization was seen to induce antigen-specific cellular and humoral immune responses (as detected ex vivo). The median time to progression was 10.2 months (95% confidence interval [CI]: 5.7–12.6) and median survival was 22.8 months (95% CI: 17.5–29). Patient survival was compared to that based on recursive partition analysis. Of the 12 trial patients, eight were in group III, with the remaining in group IV. As patients in these groups have an expected survival of 17.9 and 11.1 months, respectively, nine of 12 study patients were seen to exceed these expectations. While this difference did not reach statistical significance ($P = 0.083$), the results may have been negatively biased as EGFRvIII expression was not a criterion for inclusion.

The promising results of PEPvIII-KLH in the Phase I toxicity trial led to the initiation of a second clinical trial. Due to the expense and variability associated with the use of DCs, further studies only administered PEPvIII-KLH in combination with GM-CSF. The second trial, A Complimentary Trial of an Immunotherapy Vaccine Against Tumor Specific EGFRvIII (ACTIVATE), was performed at the Duke University Medical Center and MD Anderson Cancer Center. Eighteen patients with newly diagnosed EGFRvIII expressing GBM (as detected via immunohistochemistry on paraffin-embedded tissue) having a gross total resection (>95%), Karnofsky performance status (KPS) ≥80, and not exhibiting radiographic progression following external beam radiotherapy and concurrent temozolomide were included in the trial. The median age of the cohort was 52 years, with a mean KPS of 91.7. Patients were intradermally administered PEPvIII-KLH/CDX-110 in GM-CSF, receiving three vaccinations every 2 weeks and monthly thereafter until progression. Toxicity was mostly limited to injection site reactions and was never more severe than grade II toxicity. One patient developed asymptomatic areas of T2-signal hyperintensity which was thought to be grade I leukoencephalopathy toxicity. The median time to progression was 14.2 months and median OS was 26.0 months. This survival was significantly better than that seen in a temozolomide-treated matched control group (hazard ratio [HR]: 5.1; 95% CI: 1.9–13.9; $P = 0.001$) (Figure 3). As seen in the in vivo studies, the majority of recurrent tumors (82%) had lost EGFRvIII expression at recurrence. The serum of 14 patients was analyzed for EGFRvIII-specific humoral responses, with six inducing such a response. The median OS of patients who developed EGFRvIII-specific antibody responses was 47.7 months, compared to 22.8 months in those who did not develop antibody responses ($P = 0.025$). Assessment of cellular immune responses showed three of 17 patients to have a positive delayed-type hypersensitivity (DTH) response. Patients who developed PEPvIII-specific DTH responses had a significantly longer PFS and OS ($P = 0.03$).

A third clinical trial (Phase II; ACTII) was designed to assess the efficacy of PEPvIII-KLH with standard-dose (STD) and dose-intensified (DI) temozolomide regimens in 22 patients. Patients in group A were assigned to receive temozolomide at a dose of 200 mg/m² for 5 days of a 28 day cycle, with those in group B receiving 100 mg/m² for 21 days of a 28 day cycle. Immunization with PEPvIII-KLH...
with GM-CSF was performed on day 21 of each 28-day temozolomide cycle. The mean cohort age was 57 years, with most patients (64%) having a KPS of 100. There was minimal toxicity, with no significant elevations in autoimmunity markers and no development of new T2 abnormalities. All immunized patients developed EGFRvIII-specific humoral responses, with only patients in the DI group having DTH responses. Interestingly, despite inducing more severe lymphopenia, treatment with DI temozolomide enhanced humoral and cellular immune responses following vaccination compared to STD temozolomide. As previously seen, 91.6% of recurrent tumors had lost expression of EGFRvIII. The median PFS was 15.2 months, with patients having a median OS of 23.6 months. These outcomes were significantly better than historical controls, with survival significantly exceeding the survival expectations of Curran’s recursive partitioning analysis ($P < 0.0001$) and the EORTC 26981/22981-NCIC CE3 Phase III randomized trial ($P = 0.0088$) (Figure 3).

Another Phase II trial (ACTIII) to study the efficacy of PEPvIII-KLH/rindopepimut in a larger population of newly diagnosed GBMs was then initiated.\textsuperscript{95} This study enrolled 65 patients, with therapy including temozolomide maintenance therapy (150–200 mg/m\textsuperscript{2} for 5/28 days) and three vaccinations every 2 weeks and then on the 21st day of each temozolomide cycle monthly (Figure 4). The median age was 56 years, with studied patients having a median KPS of 90. Toxicity in this trial included grade I–II injection site reactions, a grade II hypersensitivity reaction, and a case with grade III toxic epidermal necrolysis. The median PFS was 12.3 months and OS was 24.6 months, both of which were significantly higher than historical controls ($P = 0.0088$ and $<0.0001$, respectively) (Figure 3). As expected, patients with methylated MGMT had a significantly higher PFS (17.5 vs 11.2 months; $P = 0.0057$) and OS (32.3 vs 20.9 months; $P = 0.0067$).

### Ongoing clinical trials

Currently there are two active trials investigating the use of rindopepimut in GBM. A Phase III trial (ACT IV) has been initiated to investigate the safety and efficacy of rindopepimut in newly diagnosed GBM (Figure 3). This international trial is being conducted at over 100 centers and will include ~374 patients with a gross total resection. Additionally, patients having incomplete resections will be enrolled, allowing for the evaluation of rindopepimut efficacy in patients with residual tumor burden. All patients will only receive two priming vaccines (compared to three in previous trials). The estimated completion date is November 2016. Another Phase II trial (ReACT) is investigating the efficacy of rindopepimut in combination with bevacizumab in patients with relapsed EGFRvIII-positive GBM. Patients will be enrolled into two groups: Group 1 patients will be randomly assigned to receive either rindopepimut or KLH, each with bevacizumab; Group 2 patients will all be treated with rindopepimut in combination with bevacizumab and consists of those refractory to bevacizumab. The primary outcome measure is PFS rate at 6 months, with secondary outcomes being safety and tolerability, antitumor activity, and EGFRvIII-specific immune response. As tumor volume is not an exclusion criterion in this trial, the efficacy of rindopepimut in cases with significant tumor burden will also be evaluated. This study will seek to enroll 95 patients and has an estimated primary completion date of March 2014.

![Timeline demonstrating the schedule of treatment for glioblastoma patients undergoing immunotherapy with rindopepimut.](image)

**Figure 4** Timeline demonstrating the schedule of treatment for glioblastoma patients undergoing immunotherapy with rindopepimut.

**Abbreviation:** GBM, glioblastoma multiforme.
Limitations

While rindopepimut is efficacious and safe for the treatment of GBM, there are several limitations. Firstly, as EGFRvIII is only expressed in a small number of GBMs (~20%-30%), rindopepimut cannot be used to treat the majority of GBM cases. Therefore, immunotherapy directed toward other tumor-specific targets such as cytomegalovirus antigens may allow for more widespread use. Rindopepimut also has limited utility for the continued treatment of cases with tumor recurrence despite vaccine therapy as most of these tumors lose EGFRvIII expression. Additionally, the performed clinical trials have had several shortcomings. Firstly, all patients did not receive salvage therapy uniformly for tumor progression as the use of additional agents was the discretion of the patient’s neurooncologist. This may introduce bias by affecting OS. The presence of isocitrate dehydrogenase 1/2 (IDH1/2) mutations was not determined in enrolled patients. These mutations which occur most commonly in secondary GBMs significantly predict survival and may confer a survival advantage.96–98 As a result, an overrepresentation of these mutations in the study cohort may artificially improve OS compared to historical controls. However, as EGFRvIII is rarely expressed in secondary GBMs, the effect of IDH1/2 mutations is likely minor as the ACTIVATE, ACTII, and ACTIII trials only enrolled patients with EGFRvIII-expressing tumors. In addition to the small sample sizes in the current studies, only patients with a high performance status and those not having evidence of disease progression following chemoradiotherapy were enrolled. These inclusion criteria result in the selection of patients having an overall better prognosis and thus introduce significant selection bias. Also, all patients underwent image verified gross total resections. This was intended to minimize the immunosuppressive effects of the tumor mass. As a significant percentage of GBM patients do not receive gross total resection, the efficacy of rindopepimut in these cases is unclear. The use of inhibitors to negate the effects of various immunosuppressive cascades such as the signal translation and activator of transcription-3 pathway may improve the efficacy of rindopepimut in cases with significant residual disease.

Conclusion

Rindopepimut (PEPvIII-KLH/CDX-110) is an effective EGFRvIII-targeted immunotherapy which appeared to improve PFS and OS in Phase I and II clinical trials for patients with EGFRvIII-expressing GBMs. Serious adverse reactions are rare, with patients typically only experiencing hypersensitivity reactions at the injection site. Currently, a Phase II trial for relapsed GBM and a Phase III trial for newly diagnosed cases are ongoing and will provide additional data regarding the efficacy of rindopepimut in the near future. While rindopepimut has limitations, it is a promising therapy for patients with EGFRvIII-expressing GBMs and significantly adds to our arsenal for combating this aggressive disease. There remains a paucity of approved immunotherapies in oncology (therapeutic one for prostate cancer and preventive one for cervical cancer), but we are optimistic that studies on therapies like rindopepimut will identify therapies that will prove efficacious in the general population.

Disclosure

The authors have no financial or institutional interest in any of the drugs, materials, or devices described in this article, or any other type of conflict of interest.

References


